Journal of Clinical Pathology and Laboratory Medicine

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Perspective - Journal of Clinical Pathology and Laboratory Medicine (2023) Volume 5, Issue 6

The transformative era of oncological diagnostics: Liquid profiling paving the way

Raffaella Cinieri*

Department of Oncology, University of Delaware, United States

*Corresponding Author:
Raffaella Cinieri
Department of Oncology, University of Delaware, United States
University of Delaware
United States

Received:28-Nov-2023, Manuscript No. AACPLM-23-121796; Editor assigned: 01-Dec-2023, PreQC No. AACPLM-23-121796(PQ); Reviewed:15-Dec-2023, QC No. AACPLM-23-121796; Revised:20-Dec -2023, Manuscript No. AACPLM-23-121796(R); Published:27-Dec-2023, DOI:10.35841/ aacplm-5.6.177

Citation: Cinieri R. The transformative era of oncological diagnostics: Liquid profiling paving the way. J Clin Path Lab Med. 2023;5(6):177


Cancer, a relentless adversary to human health, has long challenged the medical community's arsenal of diagnostic tools. However, in recent years, a revolutionary approach known as liquid profiling has emerged as a beacon of hope in the realm of oncological diagnostics. This ground-breaking method has transformed the landscape of cancer detection and monitoring, offering a non-invasive and comprehensive means of understanding and managing this complex disease[1].

Traditionally, the diagnosis and monitoring of cancer involved invasive procedures such as tissue biopsies, which often posed risks and limitations. However, liquid profiling harnesses the power of biological fluids like blood, urine, and saliva, leveraging the wealth of information carried within these bodily fluids[2].

At the heart of liquid profiling are circulating biomarkers—molecules shed by tumors into the bloodstream. These biomarkers include Circulating Tumor Cells (CTCs), cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), exosomes, and various proteins. By analyzing these biomarkers through advanced technologies like Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and other high-throughput methods, clinicians can gain valuable insights into the genetic makeup and characteristics of tumors without the need for invasive procedures[3].

One of the key advantages of liquid profiling lies in its ability to provide a holistic view of the tumor’s genetic landscape. This comprehensive analysis enables clinicians to identify specific mutations, genetic alterations, and biomarker profiles unique to an individual's cancer. Such personalized information is instrumental in tailoring targeted therapies, predicting treatment response, and monitoring disease progression with greater precision[4].

Liquid profiling has also showcased its potential as a tool for early cancer detection. The ability to detect minute traces of circulating tumor DNA or other biomarkers in bodily fluids offers a promising avenue for detecting cancer at its nascent stages, potentially leading to timely interventions and improved patient outcomes [5].

Furthermore, this approach facilitates real-time monitoring of a patient's response to treatment and the emergence of treatment-resistant mutations. By periodically analyzing circulating biomarkers, clinicians can adapt treatment strategies swiftly, making informed decisions to optimize therapy and mitigate the risk of disease progression[6].

The applications of liquid profiling extend beyond diagnosis and monitoring. Researchers are exploring its utility in predicting the risk of cancer recurrence after initial treatment, guiding decisions regarding adjuvant therapies, and assessing minimal residual disease—areas crucial for improving long-term survival rates and quality of life for cancer survivors[7].

However, despite its immense potential, liquid profiling is not without challenges. Standardization of techniques, validation of biomarkers, and the need for larger-scale clinical studies to establish its widespread utility remain areas of active research and development[8].

As we celebrate the strides made in oncological diagnostics on this special occasion, it's evident that liquid profiling stands at the forefront of a transformative era. Its promise in revolutionizing cancer care by offering non-invasive, personalized, and dynamic insights into this complex disease heralds a new dawn in the fight against cancer[9].

In conclusion, while the journey to harness the full potential of liquid profiling may have hurdles, its impact on reshaping the landscape of oncological diagnostics is undeniable. With continued advancements and collaborative efforts among researchers, clinicians, and technology innovators, the future holds immense promise for liquid profiling to become an indispensable tool in the fight against cancer[10].


  1. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378-81.
  2. Indexed at, Google Scholar, Cross Ref

  3. Gardy JL, Loman NJ. Towards a genomics-informed, real-time, global pathogen surveillance system. Nat Rev Genet. 2018;19(1):9-20.
  4. Indexed at, Google Scholar, Cross Ref

  5. Hudson Chairperson TJ, Anderson W, Aretz A, et al. International network of cancer genome projects.2010.
  6. Indexed at, Google Scholar, Cross Ref

  7. Weinstein JN, Collisson EA, Mills GB, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):1113-20.
  8. Indexed at, Google Scholar, Cross Ref

  9. Soong R, Syn N, Wang K, et al. Precision oncology: Mind the disruption. Biochem. 2016;38(1):14-8.
  10. Indexed at, Google Scholar, Cross Ref

  11. Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270(5235):467-70.
  12. Indexed at, Google Scholar, Cross Ref

  13. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science. 1999;286(5439):531-7.
  14. Indexed at, Google Scholar, Cross Ref

  15. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-11.
  16. Indexed at, Google Scholar, Cross Ref

  17. Van't Veer LJ, Dai H, Van De Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-6.
  18. Indexed at, Google Scholar, Cross Ref

  19. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-26.
  20. Indexed at, Google Scholar, Cross Ref

Get the App